| Stereochemistry | ACHIRAL |
| Molecular Formula | C22H23Cl2N3OS.ClH |
| Molecular Weight | 484.869 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 1 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.CN1CCN(CC1)C2=CC=CC=C2\C=C3/SCCN(C3=O)C4=CC=C(Cl)C(Cl)=C4
InChI
InChIKey=NMTRXBJYASHMND-UXTSPRGOSA-N
InChI=1S/C22H23Cl2N3OS.ClH/c1-25-8-10-26(11-9-25)20-5-3-2-4-16(20)14-21-22(28)27(12-13-29-21)17-6-7-18(23)19(24)15-17;/h2-7,14-15H,8-13H2,1H3;1H/b21-14-;
Elzasonan (CP 448187) is a serotonin 1B/1D receptor antagonist. Elzasonan was primarily metabolized via oxidative N‐demethylation, N‐oxidation, and aryl hydroxylation. Pfizer was developing elzasonan for the treatment of anxiety and affective disorders however development has been discontinued.
CNS Activity
Originator
Approval Year
PubMed
Patents
ACTIVE MOIETY
SUBSTANCE RECORD
